Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Analysts
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has received a consensus "Buy" rating from thirteen brokerages, with an average one-year price target of $54.73. Despite insider selling, institutional ownership remains high at 95.45%. The company focuses on developing small-molecule drugs targeting ion channels for neurological and pain disorders.
Xenon (NASDAQ:XENE) Short-Term Positioning Shifts In Nasdaq Futures
Xenon (NASDAQ:XENE) is seeing short-term positioning shifts in Nasdaq Futures due to significant put option activity and institutional rotation in biotech trading. The article highlights that clinical progress, derivatives, institutional holdings, and broader biotech sentiment are key factors influencing Xenon's market perception. Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on ion-channel therapies for neurological and pain disorders.
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)
Xenon Pharmaceuticals (NASDAQ:XENE) experienced unusually high options trading activity, with traders acquiring 4,063 put options, a 2,362% increase over the average, signaling bearish sentiment. This comes despite the stock having a consensus "Buy" rating and trading higher on the reported day. The article also notes significant insider selling, including a large transaction by the CEO, alongside institutional inflows and various analyst ratings.
Aberdeen Group plc Has $23.25 Million Holdings in Xenon Pharmaceuticals Inc. $XENE
Aberdeen Group plc increased its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 11.1% to 579,145 shares, valued at $23.25 million, making up approximately 0.75% of the company. Despite this, Xenon's CEO, Ian Mortimer, significantly reduced his holdings by selling 40,000 shares for $1.78 million, while other insiders sold a total of 65,302 shares. Brokerages have largely issued "Buy" ratings with an average price target of $54.73, while the company's stock currently trades at $41.66.
Understanding Momentum Shifts in (XENE)
This article analyzes Xenon Pharmaceuticals Inc. (XENE) using AI models, identifying a neutral near- and mid-term outlook with a moderate long-term positive bias. It highlights a significant 36.4:1 risk-reward short setup and outlines three trading strategies—Position, Momentum Breakout, and Risk Hedging—alongside multi-timeframe signal analysis for support and resistance levels. The report emphasizes real-time signals, risk management, and predictive AI insights for traders.
Xenon Pharma To Report Epilepsy Trial Results Next Month
Xenon Pharmaceuticals Inc. (XENE) is nearing a significant milestone with its lead drug candidate, Azetukalner, for epilepsy, major depressive disorder, and bipolar depression. The company expects to release topline data from its Phase 3 X-TOLE2 trial for focal onset seizures in March 2026, with a New Drug Application submission planned for the second half of the year. XENE also has other drug candidates, XEN1701 and XEN1120, in Phase 1 trials for acute pain, with studies expected to complete in 2026.
Xenon Pharma To Report Epilepsy Trial Results Next Month
Xenon Pharmaceuticals Inc. is nearing a significant milestone with its lead drug candidate, Azetukalner, for epilepsy. The company is set to release topline data from its phase 3 X-TOLE2 trial in March 2026, with a New Drug Application submission planned for later in the year. Additionally, Xenon is advancing other studies for Azetukalner in major depressive disorder and bipolar depression, and developing two drug candidates for acute pain, XEN1701 and XEN1120.
Avoiding Lag: Real-Time Signals in (XENE) Movement
This article provides real-time signal analysis for Xenon Pharmaceuticals Inc. (NASDAQ: XENE), indicating a neutral near and mid-term outlook with a potential moderation of its long-term positive bias. It highlights a mid-channel oscillation pattern and offers three AI-generated institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The report also includes multi-timeframe signal analysis, showing varying signal strengths across different holding periods.
J. Safra Sarasin Holding AG Sells 51,880 Shares of Xenon Pharmaceuticals Inc. $XENE
J. Safra Sarasin Holding AG significantly reduced its stake in Xenon Pharmaceuticals Inc. by selling 51,880 shares, now owning 30,168 shares valued at approximately $1.21 million. This follows insider selling by CEO Ian Mortimer who sold 40,000 shares for $1.78 million, reducing his holding to 6,000 shares. Despite these sales, institutional investors own 95.45% of the stock, and analysts maintain a "Buy" consensus with a price target of $54.82.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Analysts
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has received a consensus "Buy" rating from analysts, with an average 12-month target price of $54.82. Despite this positive outlook, CEO Ian Mortimer recently sold a significant portion of his shares. The company shows heavy institutional ownership, with major funds increasing their stakes.
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)
Xenon Pharmaceuticals (NASDAQ:XENE) experienced unusually high options trading volume on Wednesday, with put options increasing by approximately 2,362% compared to the daily average. This comes amidst significant insider selling, including CEO Ian Mortimer reducing his stake by nearly 87%, even as analysts maintain an average "Buy" rating with a price target above the current trading price. The company reported quarterly EPS of ($1.15), beating consensus estimates.
Campbell & CO Investment Adviser LLC Takes Position in Xenon Pharmaceuticals Inc. $XENE
Campbell & CO Investment Adviser LLC acquired a new position of 28,669 shares in Xenon Pharmaceuticals Inc. during the third quarter, valued at approximately $1.15 million. This comes as institutional investors now own 95.45% of the biopharmaceutical company's stock, despite recent insider selling by CEO Ian Mortimer. Analysts generally maintain a "Buy" rating for XENE, with a consensus target price of $54.82.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants totaling 42,300 share options to ten new non-officer employees. These grants, approved by the Compensation Committee, were made under Nasdaq Listing Rule 5635(c)(4) with an exercise price of $40.74 per common share, matching the closing price on January 15, 2026. The options vest over four years, tied to continued employment, and are part of the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan.
Ten new Xenon hires receive 42,300 stock options vesting over 4 years
Xenon Pharmaceuticals (Nasdaq: XENE) announced that it has granted 42,300 inducement stock options to ten new non-officer employees. The options have an exercise price of $40.74 per share, matching the closing price on the grant date of January 15, 2026, and will vest over four years. This move is part of the company's strategy to attract new talent in accordance with Nasdaq Listing Rule 5635(c)(4).
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants of an aggregate of 42,300 share options to ten new non-officer employees. These grants were approved by the Compensation Committee and are material inducements for employment, complying with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $40.74, based on the closing price on January 15, 2026, and vest over four years.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants of 42,300 share options to ten new non-officer employees. These grants, approved by the Compensation Committee, have an exercise price of $40.74 per common share and vest over four years, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are intended to incentivize employees beginning their tenure with the company.
Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pressure And DCF Upside Potential
Xenon Pharmaceuticals (XENE) has seen recent share price pressure, with a 1-month decline of 8.4% and a year-to-date decline of 9.3%, despite a strong 5-year total shareholder return of 152.7%. Simply Wall St's discounted cash flow (DCF) model estimates a fair value of US$384.76, significantly above its current trading price of US$40.36, suggesting the stock might be undervalued. However, the company is still unprofitable, and its Price-to-Book ratio of 5.6x is above the industry average, indicating mixed signals for investors depending on their valuation approach.
New seizure and depression drug faces key 2026 test in late-stage trials
Xenon Pharmaceuticals outlined its clinical and regulatory milestones at the 2026 J.P. Morgan Healthcare Conference, focusing on its lead drug azetukalner. The company expects topline data for its Phase 3 X-TOLE2 study in focal onset seizures by March 2026, with an NDA submission anticipated in the second half of 2026. Additionally, Xenon is advancing five other Phase 3 studies for azetukalner in epilepsy and neuropsychiatry, including X-NOVA2 for major depressive disorder with data expected in H1 2027, and progressing early-stage pain candidates XEN1701 and XEN1120 with Phase 1 data due in 2026.
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
Xenon Pharmaceuticals outlined key upcoming milestones at the 2026 J.P. Morgan Healthcare Conference, including anticipated topline data from its Phase 3 X-TOLE2 study for azetukalner in focal onset seizures in March 2026, followed by an NDA submission in H2 2026. The company also detailed ongoing Phase 3 studies for azetukalner in epilepsy and neuropsychiatry, with X-NOVA2 data for MDD expected in H1 2027, and Phase 1 data for novel pain candidates XEN1701 and XEN1120 due in 2026 to support future Phase 2 studies.
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
Xenon Pharmaceuticals Inc. has outlined significant upcoming milestones, including anticipated topline data in March 2026 for its Phase 3 X-TOLE2 study of azetukalner for focal onset seizures, with an NDA submission planned for H2 2026. The company is also progressing five other Phase 3 azetukalner studies in epilepsy and neuropsychiatry, and expects data from two Phase 1 studies for novel pain candidates in 2026 to support future Phase 2 trials. These updates were shared at the 2026 J.P. Morgan Healthcare Conference, highlighting the company's advancement in its neuroscience-focused pipeline.
JPMorgan reiterates Overweight rating on Xenon Pharmaceuticals stock By Investing.com
JPMorgan has reiterated an Overweight rating on Xenon Pharmaceuticals (NASDAQ:XENE) with a price target of $62.00, suggesting a significant upside. The positive outlook is primarily based on the anticipated topline data release in early 2026 for its phase 3 X-TOLE2 trial, evaluating azetukalner for focal onset seizures. This aligns with a broader "Strong Buy" consensus among analysts, with Cantor Fitzgerald also raising its price target on Xenon due to a strong pipeline beyond seizure treatments.
Cantor Fitzgerald eleva preço-alvo das ações da Xenon Pharmaceuticals para US$ 55
Cantor Fitzgerald increased its price target for Xenon Pharmaceuticals (NASDAQ:XENE) shares to $55 from $45, reiterating an "Outperform" rating. The firm noted that the increased valuation primarily stems from Xenon's broad pipeline, especially its Phase 3 depression program, rather than its existing seizure treatments. Xenon, currently trading near its 52-week high, shows strong financial health with more cash than debt and a high current ratio, positioning it well for development programs.
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)
Xenon Pharmaceuticals (NASDAQ:XENE) experienced unusually high options trading volume, with investors purchasing 4,063 put options, representing a 2,362% increase. This activity follows CEO Ian Mortimer's sale of 40,000 shares for $1.78 million, significantly reducing his direct holdings, and institutional investors adjusting their stakes. Despite the insider selling, analysts maintain a "Buy" rating with a consensus price target of $54.64.
Cantor Fitzgerald raises Xenon Pharmaceuticals stock price target to $55
Cantor Fitzgerald has increased its price target for Xenon Pharmaceuticals (NASDAQ:XENE) to $55.00 from $45.00, reiterating an Overweight rating. The firm notes that Xenon's broader pipeline, beyond its seizure treatments, is the primary driver of this increased valuation, with its upcoming XTOLE-2 catalyst being less critical. Despite not being profitable yet, Xenon maintains strong financial health with more cash than debt and a high current ratio.
Why Xenon Pharmaceuticals stock is down today as JPM Healthcare Conference nears
Xenon Pharmaceuticals (XENE) shares dropped 6.5% on Monday, January 5, 2026, ahead of the J.P. Morgan Healthcare Conference, despite a supportive analyst note from Cantor Fitzgerald. Investors are awaiting updates on the company's lead molecule, azetukalner, which is in Phase 3 trials for epilepsy and mood disorders, with topline data for its X-TOLE2 epilepsy study expected in early 2026. The biotech sector as a whole experienced a softer trading day, with XENE's decline being steeper than the general trend.
Xenon Pharmaceuticals Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference in January 2026
Xenon Pharmaceuticals Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, with CEO Ian Mortimer speaking on January 12th. The company, focused on neurological therapeutics, is advancing its lead molecule azetukalner in Phase 3 trials for epilepsy and mood disorders, along with other pipeline candidates for pain management. The article also provides details on recent insider trading, hedge fund activity, and analyst ratings for XENE stock.
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
Xenon Pharmaceuticals Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026. Ian Mortimer, President and CEO, will provide the company presentation on January 12th. A live audio webcast will be available on Xenon's investor relations website.
About Us | Oil & Gas Journal - Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
Xenon Pharmaceuticals Inc. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled from January 12-15, 2026, in San Francisco. President and CEO Ian Mortimer will present on January 12 at 9:00-9:40 AM Pacific Time. The presentation will be webcast live and available for replay on the company's investor relations website.
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The company's presentation will be on Monday, January 12, 2026, from 9:00-9:40 AM Pacific Time, delivered by Ian Mortimer, President and CEO. A live audio webcast will be available on the Investors section of Xenon's website.
(XENE) Movement Within Algorithmic Entry Frameworks
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is exhibiting neutral near and mid-term readings, potentially moderating a long-term positive bias. The analysis highlights a 41.1:1 risk-reward short setup and provides institutional trading strategies for various risk profiles. These strategies include specific entry, target, and stop-loss zones for long, breakout, and short positions.
Xenon Pharmaceuticals (NASDAQ:XENE) CEO Ian Mortimer Sells 40,000 Shares
Xenon Pharmaceuticals (NASDAQ:XENE) CEO Ian Mortimer sold 40,000 shares of the company's stock on January 2nd, 2026, at an average price of $44.43, totaling $1.78 million. Following this transaction, his position was reduced by 86.96% to 6,000 shares. The stock is currently trading around $44.49, and Wall Street maintains a consensus "Buy" rating with a price target of $54.64.
Xenon Pharmaceuticals (NASDAQ:XENE) Trading 3.8% Higher - Here's Why
Shares of Xenon Pharmaceuticals (NASDAQ:XENE) rose 3.8% on Wednesday, with light trading volume, closing at $45.7990. Despite a negative P/E ratio and recent quarterly loss, analysts are largely positive, with RBC recently raising its price target to $58. However, company insiders, including CEO Ian Mortimer, have been selling shares, reducing their holdings significantly.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novavax (NVAX), Xenon (XENE) and Biohaven Ltd. (BHVN)
Analysts have provided mixed ratings for several healthcare stocks. Novavax (NVAX) received a Hold consensus with Bank of America Securities maintaining a Sell rating, while Biohaven Ltd. (BHVN) garnered a Moderate Buy consensus from J.P. Morgan and Leerink Partners.
Commit To Purchase Xenon Pharmaceuticals At $32.50, Earn 25.8% Annualized Using Options
Investors looking at Xenon Pharmaceuticals Inc (XENE) stock at $44.76/share can consider selling a July 2026 put at the $32.50 strike for a premium of $4.60. This strategy yields a 14.2% return on commitment, or an annualized rate of 25.8%, benefiting the seller unless the stock falls by more than 27.5% and the option is exercised. The article includes a chart of XENE's historical trading and emphasizes evaluating risk versus reward in combination with fundamental analysis.
Stifel reiterates Buy rating on Xenon Pharmaceuticals stock amid competitor setback
Stifel has maintained its Buy rating and $60.00 price target for Xenon Pharmaceuticals (NASDAQ:XENE) after a competitor, Biohaven (BHVN), experienced a clinical trial failure in major depressive disorder (MDD). Stifel views this setback for Biohaven's Kv7 compound as strengthening Xenon's XEN1101, a similar class of drug, due to Biohaven's limited efficacy evidence and financial challenges. The firm remains confident in Xenon's approach despite MDD being a risky indication for the Kv7 drug class.
Stifel mantém recomendação de compra para ações da Xenon Pharmaceuticals após revés de concorrente
Stifel reiterated its buy rating and $60 price target for Xenon Pharmaceuticals (NASDAQ:XENE) after a competitor's clinical trial for major depressive disorder (MDD) failed. The firm believes Xenon's compound, XEN1101, a similar class drug, has greater potential than Biohaven's Kv7 compound, BHV-7000. Biohaven's stock has seen a significant decline, and the company is not expected to be profitable this year, according to InvestingPro data.
Traders Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)
Traders have significantly increased their purchase of put options for Xenon Pharmaceuticals (NASDAQ:XENE), with an impressive 2,362% surge over typical daily volume, potentially signaling bearish sentiment or hedging. This surge occurs amidst insider sales by CEO Ian Mortimer and substantial institutional ownership, with some analysts maintaining a positive outlook and an average price target of $54.64.
Why (XENE) Price Action Is Critical for Tactical Trading
This article analyzes the price action of Xenon Pharmaceuticals Inc. (NASDAQ: XENE) for tactical trading, highlighting a near-term strong sentiment contrasting with neutral mid and long-term outlooks. It details specific trading strategies for different risk profiles, including long entry, momentum breakout, and short hedging, based on AI-generated signals and multi-timeframe analysis.
Xenon Pharmaceuticals Inc. $XENE is Braidwell LP's 7th Largest Position
Braidwell LP has significantly increased its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE), making it their 7th largest position. Other institutional investors have also adjusted their holdings, while company CEO Ian Mortimer recently sold a portion of his shares. The stock has shown positive price performance and analysts maintain a "Buy" rating with an average price target of $54.64.
Wells Fargo Maintains Xenon Pharmaceuticals (XENE) Overweight Recommendation
Wells Fargo has reiterated its "Overweight" recommendation for Xenon Pharmaceuticals (NASDAQ:XENE). Analysts project a 28.69% upside with an average one-year price target of $56.18/share, while institutional ownership shows mixed sentiment with a slight increase in total shares owned but a bearish put/call ratio.
Xenon projects top line X-TOLE2 data in early 2026 as enrollment surpasses target, expanding late-stage pipeline
Xenon Pharmaceuticals expects to release top-line data for its X-TOLE2 clinical trial in early 2026. The company has surpassed its enrollment target for this study, which will further expand its late-stage pipeline. This development indicates progress in Xenon's clinical research efforts.
Russell Investments Group Ltd. Decreases Holdings in Xenon Pharmaceuticals Inc. $XENE
Russell Investments Group Ltd. significantly reduced its stake in Xenon Pharmaceuticals Inc. by 30.8% in Q2 2025, now holding 52,136 shares valued at $1.63 million. This comes as institutional ownership in Xenon Pharmaceuticals stands at approximately 95.45%, while CEO Ian Mortimer also sold a large block of shares. The biopharmaceutical company, with a market cap of $3.36 billion, is progressing with its lead drug XEN1101 in Phase 3 trials for epilepsy, and analysts maintain an average "Buy" rating with a target price of $54.27.
XENE Stock Update: Wells Fargo Raises Price Target to $48 | XENE
Wells Fargo analyst Benjamin Burnett has raised the price target for Xenon Pharmaceuticals (XENE) to $48, while maintaining an "Overweight" rating. This adjustment reflects continued analyst optimism for the neuroscience-focused biopharmaceutical company. The average target price from 18 analysts is $55.31, implying a 25.89% upside from the current price.
Xenon projects top line X-TOLE2 data in early 2026 as enrollment surpasses target, expanding late-stage pipeline
Xenon Pharmaceuticals anticipates top-line data from its X-TOLE2 study in early 2026. The company has successfully surpassed its enrollment target for the study, indicating a strong expansion of its late-stage development pipeline. This progress is a significant step for Xenon as it moves closer to potentially bringing new treatments to market.
Ian Mortimer, Xenon Pharma CEO, sells $1.14m in shares
Ian Mortimer, CEO of Xenon Pharmaceuticals Inc. (NASDAQ:XENE), sold shares worth over $1.14 million in early December 2025 under a pre-arranged trading plan. Despite these insider sales, the company recently met Q3 earnings expectations, reporting an EPS of -1.15 USD, and has strong cash reserves until 2027 to support its late-stage clinical developments, with Cantor Fitzgerald reiterating an Overweight rating.
Ian Mortimer, Xenon Pharma CEO, sells $1.14m in shares By Investing.com
Ian Mortimer, President and CEO of Xenon Pharmaceuticals Inc. (NASDAQ:XENE), recently sold 25,205 common shares for a total of $1,142,513 through multiple transactions on December 5 and December 8, 2025. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan established on September 27, 2024. Following these transactions, Mortimer directly holds 8,010 shares, and his spouse indirectly holds an additional 14,300 shares, while Cantor Fitzgerald reiterated an Overweight rating with a $55.00 price target for XENE following Q3 earnings that met expectations.
Ian Mortimer, Xenon Pharma CEO, sells $1.14m in shares
Ian Mortimer, President and CEO of Xenon Pharmaceuticals Inc. (NASDAQ:XENE), sold 25,205 common shares for a total of $1,142,513 in early December 2025 across multiple transactions. These sales, executed under a pre-arranged trading plan, leave Mortimer with a direct ownership of 8,010 shares, while his spouse holds an additional 14,300 shares. The company recently reported Q3 earnings meeting expectations, boasts strong cash reserves through 2027, and received an Overweight rating from Cantor Fitzgerald, reflecting confidence in its clinical programs.
Marshall Wace LLP Acquires 262,109 Shares of Xenon Pharmaceuticals Inc. $XENE
Marshall Wace LLP increased its stake in Xenon Pharmaceuticals (NASDAQ:XENE) by 34.6% in the second quarter, acquiring an additional 262,109 shares, bringing their total ownership to 1,020,254 shares valued at $31.93 million. This comes amidst high institutional ownership of 95.45% and continued acquisitions by other hedge funds, while CEO Ian Mortimer recently sold a portion of his holdings. Analysts maintain a consensus "Buy" rating for XENE with a target price of $54.27.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by Brokerages
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has received a consensus "Buy" rating from fourteen analysts, with an average 12-month price target of $54.27. The company, a neuroscience-focused biopharma, is currently conducting Phase 3 trials for its lead candidate, XEN1101, for epilepsy. Insider trading activity included CEO Ian Mortimer selling 25,000 shares, reducing his holdings by 44.4%.
New York State Common Retirement Fund Purchases 24,100 Shares of Xenon Pharmaceuticals Inc. $XENE
The New York State Common Retirement Fund increased its stake in Xenon Pharmaceuticals (NASDAQ:XENE) by 16.9% in Q2, acquiring an additional 24,100 shares to hold a total of 166,472 shares valued at $5,211,000. Analyst ratings for Xenon Pharmaceuticals indicate an average "Buy" consensus with a price target of $54.27, including recent upgrades. Notably, CEO Ian Mortimer sold 25,000 shares in October, reducing his stake by 44.4%, while corporate insiders collectively own 4.07% of the company.
